BACKGROUND: The prevalence of esophageal atresia (EA) has been shown to vary across different geographical settings. Investigation of geographical differences may provide an insight into the underlying etiology of EA. METHODS: The study population comprised infants diagnosed with EA during 1998 to 2007 from 18 of the 46 birth defects surveillance programs, members of the International Clearinghouse for Birth Defects Surveillance and Research. Total prevalence per 10,000 births for EA was defined as the total number of cases in live births, stillbirths, and elective termination of pregnancy for fetal anomaly (ETOPFA) divided by the total number of all births in the population. RESULTS: Among the participating programs, a total of 2943 cases of EA were diagnosed with an average prevalence of 2.44 (95% confidence interval [CI], 2.35-2.53) per 10,000 births, ranging between 1.77 and 3.68 per 10,000 births. Of all infants diagnosed with EA, 2761 (93.8%) were live births, 82 (2.8%) stillbirths, 89 (3.0%) ETOPFA, and 11 (0.4%) had unknown outcomes. The majority of cases (2020, 68.6%), had a reported EA with fistula, 749 (25.5%) were without fistula, and 174 (5.9%) were registered with an unspecified code. CONCLUSIONS: On average, EA affected 1 in 4099 births (95% CI, 1 in 3954-4251 births) with prevalence varying across different geographical settings, but relatively consistent over time and comparable between surveillance programs. Findings suggest that differences in the prevalence observed among programs are likely to be attributable to variability in population ethnic compositions or issues in reporting or registration procedures of EA, rather than a real risk occurrence difference. Birth Defects Research (Part A), 2012.
BACKGROUND: The prevalence of esophageal atresia (EA) has been shown to vary across different geographical settings. Investigation of geographical differences may provide an insight into the underlying etiology of EA. METHODS: The study population comprised infants diagnosed with EA during 1998 to 2007 from 18 of the 46 birth defects surveillance programs, members of the International Clearinghouse for Birth Defects Surveillance and Research. Total prevalence per 10,000 births for EA was defined as the total number of cases in live births, stillbirths, and elective termination of pregnancy for fetal anomaly (ETOPFA) divided by the total number of all births in the population. RESULTS: Among the participating programs, a total of 2943 cases of EA were diagnosed with an average prevalence of 2.44 (95% confidence interval [CI], 2.35-2.53) per 10,000 births, ranging between 1.77 and 3.68 per 10,000 births. Of all infants diagnosed with EA, 2761 (93.8%) were live births, 82 (2.8%) stillbirths, 89 (3.0%) ETOPFA, and 11 (0.4%) had unknown outcomes. The majority of cases (2020, 68.6%), had a reported EA with fistula, 749 (25.5%) were without fistula, and 174 (5.9%) were registered with an unspecified code. CONCLUSIONS: On average, EA affected 1 in 4099 births (95% CI, 1 in 3954-4251 births) with prevalence varying across different geographical settings, but relatively consistent over time and comparable between surveillance programs. Findings suggest that differences in the prevalence observed among programs are likely to be attributable to variability in population ethnic compositions or issues in reporting or registration procedures of EA, rather than a real risk occurrence difference. Birth Defects Research (Part A), 2012.
Authors: Martin C H Haeusler; Andrea Berghold; Claude Stoll; Ingeborg Barisic; Maurizio Clementi Journal: Prenat Diagn Date: 2002-07 Impact factor: 3.050
Authors: J Rankin; S Pattenden; L Abramsky; P Boyd; H Jordan; D Stone; M Vrijheid; D Wellesley; H Dolk Journal: Arch Dis Child Fetal Neonatal Ed Date: 2005-09 Impact factor: 5.747
Authors: E Robert; O Mutchinick; P Mastroiacovo; L B Knudsen; A K Daltveit; E E Castilla; P Lancaster; B Källén; G Cocchi Journal: Reprod Toxicol Date: 1993 Sep-Oct Impact factor: 3.143
Authors: Florian Friedmacher; Birgit Kroneis; Andrea Huber-Zeyringer; Peter Schober; Holger Till; Hugo Sauer; Michael E Höllwarth Journal: J Gastrointest Surg Date: 2017-04-19 Impact factor: 3.452
Authors: Carolina Pinzon-Guzman; Sreedhara Sangadala; Katherine M Riera; Evgenya Y Popova; Elizabeth Manning; Won Jae Huh; Matthew S Alexander; Julia S Shelton; Scott D Boden; James R Goldenring Journal: J Clin Invest Date: 2020-08-03 Impact factor: 14.808
Authors: O Kuseyri; A Weissbach; N Bruggemann; C Klein; M Giżewska; D Karall; S Scholl-Bürgi; H Romanowska; E Krzywińska-Zdeb; A A Monavari; I Knerr; Z Yapıcı; V Leuzzi; T Opladen Journal: J Inherit Metab Dis Date: 2018-03-28 Impact factor: 4.982
Authors: Xiao Yu; Natasha Nassar; Pierpaolo Mastroiacovo; Mark Canfield; Boris Groisman; Eva Bermejo-Sánchez; Annukka Ritvanen; Sonja Kiuru-Kuhlefelt; Adriana Benavides; Antonin Sipek; Anna Pierini; Fabrizio Bianchi; Karin Källén; Miriam Gatt; Margery Morgan; David Tucker; M Aaurora Canessa; Rosa Gajardo; Osvaldo M Mutchinick; Elena Szabova; Melinda Csáky-Szunyogh; Giovanna Tagliabue; Janet D Cragan; Wendy N Nembhard; Anke Rissmann; Dorit Goetz; Carol Bower; Gareth Baynam; R Brian Lowry; Juan A Leon; Wei Luo; Jocelyn Rouleau; Ignacio Zarante; Nicolas Fernandez; Emmanuelle Amar; Saeed Dastgiri; Paolo Contiero; Laura E Martínez-de-Villarreal; Barry Borman; J E H Bergman; Hermien E K de Walle; Charlotte A Hobbs; Amy E Nance; A J Agopian Journal: Eur Urol Date: 2019-07-09 Impact factor: 20.096
Authors: Kiera Roberts; Jonathan Karpelowsky; Dominic A Fitzgerald; Soundappan S V Soundappan Journal: Pediatr Surg Int Date: 2019-02-01 Impact factor: 1.827